Biweekly dose-dense gemcitabine–oxaliplatin and dexamethasone for relapsed/refractory aggressive non-Hodgkin lymphoma: A multicenter, single-arm, phase II trial
Jae-Cheol Jo
Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea
Search for more papers by this authorJin Ho Baek
Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea
Search for more papers by this authorJe-Hwan Lee
Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Search for more papers by this authorYoung-Don Joo
Department of Hematology and Oncology, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea
Search for more papers by this authorSung-Hwa Bae
Department of Hematology and Oncology, Daegu Catholic University Hospital, Daegu, Korea
Search for more papers by this authorJung-Lim Lee
Department of Hematology and Oncology, Daegu Fatima Hospital, Daegu, Korea
Search for more papers by this authorJung-Hee Lee
Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Search for more papers by this authorDae-Young Kim
Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Search for more papers by this authorWon-Sik Lee
Department of Hematology and Oncology, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea
Search for more papers by this authorHun Mo Ryoo
Department of Hematology and Oncology, Daegu Catholic University Hospital, Daegu, Korea
Search for more papers by this authorYunsuk Choi
Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea
Search for more papers by this authorCorresponding Author
Hawk Kim
Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea
Correspondence: Hawk Kim MD PhD, Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, 877 Bangeojinsunwhan-doro, Dong-gu, Ulsan 44033, Korea. E-Mail: [email protected]Search for more papers by this authorKyoo-Hyung Lee
Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Search for more papers by this authorCoOperative Study Group A for Hematology (COSAH)
Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea
Search for more papers by this authorJae-Cheol Jo
Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea
Search for more papers by this authorJin Ho Baek
Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea
Search for more papers by this authorJe-Hwan Lee
Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Search for more papers by this authorYoung-Don Joo
Department of Hematology and Oncology, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea
Search for more papers by this authorSung-Hwa Bae
Department of Hematology and Oncology, Daegu Catholic University Hospital, Daegu, Korea
Search for more papers by this authorJung-Lim Lee
Department of Hematology and Oncology, Daegu Fatima Hospital, Daegu, Korea
Search for more papers by this authorJung-Hee Lee
Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Search for more papers by this authorDae-Young Kim
Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Search for more papers by this authorWon-Sik Lee
Department of Hematology and Oncology, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea
Search for more papers by this authorHun Mo Ryoo
Department of Hematology and Oncology, Daegu Catholic University Hospital, Daegu, Korea
Search for more papers by this authorYunsuk Choi
Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea
Search for more papers by this authorCorresponding Author
Hawk Kim
Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea
Correspondence: Hawk Kim MD PhD, Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, 877 Bangeojinsunwhan-doro, Dong-gu, Ulsan 44033, Korea. E-Mail: [email protected]Search for more papers by this authorKyoo-Hyung Lee
Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Search for more papers by this authorCoOperative Study Group A for Hematology (COSAH)
Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea
Search for more papers by this authorThe authors declare no competing interests.
Conflicts of interest: none.
Abstract
Aim
We performed a phase II study to evaluate the efficacy of combination chemotherapy consisting of gemcitabine, dexamethasone and oxaliplatin (GemDOx) as a biweekly regimen and salvage therapy in patients with relapsed or refractory aggressive non-Hodgkin lymphoma (NHL).
Methods
Gemcitabine (1000 mg/m2) and oxaliplatin (85 mg/m2) were administered intravenously on days 1 and 15, and dexamethasone (40 mg) was administered orally on days 1–4.
Results
Twenty-nine patients were enrolled, and most patients had diffuse large B-cell lymphoma (n = 18). The median age of the patients and median prior number of chemotherapy cycles were 53 (range, 26–74) years and 1 (range, 1–4) cycle, respectively. Only 17 (58.6%) and 9 (31.0%) patients completed two or more and four or more cycles, respectively, and the median number of received cycles was two (range, 1–8). Overall response rates were 27.6% (complete response in 13.8%) among intent-to-treat patients and 47.1% (complete response in 23.5%) among patients who had received at least two GemDOx cycles. Median progression-free survival and median overall survival were 3.9 and 20.5 months, respectively. The most-frequent grade 3 or 4 toxicity was neutropenia (22.9%), and no grade 3 or 4 peripheral neurotoxicity was noted.
Conclusion
GemDOx chemotherapy, therefore, showed modest activity against relapsed or refractory aggressive NHL, although toxicities were acceptable.
REFERENCES
- 1Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002–6.
- 2Velasquez WS, Cabanillas F, Salvador P et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988; 71: 117–22.
- 3Velasquez WS, McLaughlin P, Tucker S et al. ESHAP—An effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994; 12: 1169–76.
- 4Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–5.
- 5Plunkett W, Huang P, Searcy CE, Gandhi V. Gemcitabine: preclinical pharmacology and mechanisms of action. Sem Oncol 1996; 23: 3–15.
- 6Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Sem Oncol 1995; 22: 3–10.
- 7Nabhan C, Krett N, Gandhi V, Rosen S. Gemcitabine in hematologic malignancies. Curr Opin Oncol 2001; 13: 514–21.
- 8Zinzani PL, Magagnoli M, Bendandi M et al. Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann Oncol 1998; 9: 1351–3.
- 9Sallah S, Wan JY, Nguyen NP. Treatment of refractory T-cell malignancies using gemcitabine. Brit J Haematol 2001; 113: 185–7.
- 10Crump M, Baetz T, Couban S et al. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: A phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer 2004; 101: 1835–42.
- 11Raymond E, Faivre S, Woynarowski JM, Chaney SG. Oxaliplatin: Mechanism of action and antineoplastic activity. Semin Oncol 1998; 25: 4–12.
- 12Hartmann JT, Lipp HP. Toxicity of platinum compounds. Exp Opin Pharmacother 2003; 4: 889–901.
- 13Germann N, Brienza S, Rotarski M et al. Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non-Hodgkin's lymphoma patients. Ann Oncol 1999; 10: 351–4.
- 14Chau I, Webb A, Cunningham D et al. An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma. Br J Haematol 2001; 115: 786–92.
- 15Corazzelli G, Capobianco G, Arcamone M et al. Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma. Cancer Chemother Pharmacol 2009; 64: 907–16.
- 16El Gnaoui T, Dupuis J, Belhadj K et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol 2007; 18: 1363–8.
- 17Sampol A, Rodriguez J, Galmes B, Gutierrez A, Besalduch J. Gemcitabine and oxaliplatinum: an effective regimen in a patient with progressive refractory mantle cell lymphoma. Leuk Lymphoma 2004; 45: 1289–91.
- 18Cheson BD, Pfistner B, Juweid ME et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579–86.
- 19Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1–10.
- 20Aviles A, Neri N, Huerta-Guzman J, Fernandez R. Gemcitabine and cisplatin in refractory malignant lymphoma. Oncology 2004; 66: 197–200.
- 21Ng M, Waters J, Cunningham D et al. Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. Br J Cancer 2005; 92: 1352–7.
- 22Kim KH, Joo YD, Sohn CH et al. Gemcitabine, etoposide, cisplatin, and dexamethasone in patients with refractory or relapsed non-Hodgkin's lymphoma. Korean J Intern Med 2009; 24: 37–42.
- 23Lignon J, Sibon D, Madelaine I et al. Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leukemia 2010; 10: 262–9.
- 24Ahn HK, Kim SJ, Hwang DW et al. Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/T-cell lymphoma. Investig New Drugs 2013; 31: 469–72.
- 25Muller-Beissenhirtz H, Kasper C, Nuckel H, Duhrsen U. Gemcitabine, vinorelbine and prednisone for refractory or relapsed aggressive lymphoma, results of a phase II single center study. Ann Hematol 2005; 84: 796–801.
- 26Lotfi K, Mansson E, Chandra J et al. Pharmacological basis for cladribine resistance in a human acute T lymphoblastic leukaemia cell line selected for resistance to etoposide. Brit J Haematol 2001; 113: 339–46.
- 27Fossa A, Santoro A, Hiddemann W et al. Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3786–92.
- 28Dumontet C, Morschhauser F, Solal-Celigny P et al. Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma. Br J Haematol 2001; 113: 772–8.
- 29Peters GJ, Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Braakhuis BJ. Interaction between cisplatin and gemcitabine in vitro and in vivo. Sem Oncol 1995; 22: 72–9.
- 30Pfreundschuh MG, Rueffer U, Lathan B et al. Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: A trial of the German Hodgkin's Disease Study Group. J Clin Oncol 1994; 12: 580–6.
- 31Josting A, Rudolph C, Reiser M et al. Time-intensified dexamethasone/cisplatin/cytarabine: An effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol 2002; 13: 1628–35.
- 32Barton S, Hawkes EA, Cunningham D et al. Rituximab, gemcitabine, cisplatin and methylprednisolone (R-GEM-P) is an effective regimen in relapsed diffuse large B-cell lymphoma. Eur J Haematol 2015; 94: 219–26.
- 33Sirohi B, Cunningham D, Norman A et al. Gemcitabine, cisplatin and methylprednisolone (GEM-P) with or without Rituximab in relapsed and refractory patients with diffuse large B cell lymphoma (DLBCL). Hematology (Amsterdam, Netherlands) 2007; 12: 149–53.
- 34Papageorgiou ES, Tsirigotis P, Dimopoulos M et al. Combination chemotherapy with gemcitabine and vinorelbine in the treatment of relapsed or refractory diffuse large B-cell lymphoma: A phase-II trial by the Hellenic Cooperative Oncology Group. Eur J Haematol 2005; 75: 124–9.
- 35Morschhauser F, Depil S, Jourdan E et al. Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma. Ann Oncol 2007; 18: 370–5.
- 36Park BB, Kim WS, Eom HS et al. Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin's lymphoma: A consortium for improving survival of lymphoma (CISL) trial. Investig New Drugs 2011; 29: 154–60.
- 37Crump M, Kuruvilla J, Couban S et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol 2014; 32: 3490–6.
